Inactive Instrument

Clarus Therapeutics Holdings, Inc.

Equities

CRXT

US18271L1070

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Clarus Therapeutics Holdings, Inc. Went Out of Business CI
First Amended Combined Liquidation Plan and Disclosure Statement Approved for Clarus Therapeutics Holdings, Inc. CI
First Motion for Exclusivity Period Extension Approved For Clarus Therapeutics Holdings, Inc. CI
First Motion for Exclusivity Period Extension Filed by Clarus Therapeutics Holdings, Inc. CI
First Amended Combined Liquidation Plan and Disclosure Statement Approved on Interim Basis for Clarus Therapeutics Holdings, Inc. CI
First Amended Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc. CI
Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc. CI
Clarus Therapeutics Holdings, Inc. Announces Termination of Robert Dudley as Chief Executive Officer CI
Clarus Therapeutics Holdings, Inc. Announces Termination of Steven Bourne as Chief Financial Officer, Effective November 14, 2022 CI
Clarus Therapeutics Holdings, Inc. Announces Executive Changes CI
Motion for Asset Sale Approved for Clarus Therapeutics Holdings, Inc. CI
Bidding Procedure Approved for Clarus Therapeutics Holdings, Inc. CI
Motion for Joint Administration Approved for Clarus Therapeutics Holdings, Inc. CI
Health Care Up on Deal Activity -- Health Care Roundup DJ
Motion for Asset Sale Filed by Clarus Therapeutics Holdings, Inc. CI
Motion for Joint Administration Filed by Clarus Therapeutics Holdings, Inc. CI
Clarus Therapeutics Holdings, Inc. Filed for Bankruptcy CI
Clarus Therapeutics Holdings, Inc.(NasdaqGM:CRXT) dropped from S&P TMI Index CI
Clarus Therapeutics Holdings, Inc.(NasdaqGM:CRXT) dropped from NASDAQ Composite Index CI
Top Premarket Decliners MT
North American Morning Briefing : Stock Futures -2- DJ
Needham & Co Downgrades Clarus Therapeutics to Hold From Buy MT
Maxim Downgrades Clarus Therapeutics Holdings to Hold From Buy MT
Sector Update: Health Care Stocks Cross Friday Finish Line Slightly Higher MT
Sector Update: Health Care Stocks a Rare Positive in Friday Trading MT
Chart Clarus Therapeutics Holdings, Inc.
More charts
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company. The Company is engaged in the development of androgen-based medicines. The Company is focused on the commercialization of JATENZO, which is an oral testosterone replacement or testosterone replacement therapy (TRT). JATENZO is a created by the linkage of T with the fatty acid undecanoic acid to form testosterone undecanoate. JATENZO is developed for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. It also focuses on the signs and symptoms associated with hypogonadism such as psychosexual symptoms, body mass index, fat mass and bone mineral density. The Company's subsidiary is Clarus Therapeutics, Inc.
More about the company